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While genetic advances have successfully defined part of the complexity in Parkinson’s
disease (PD), the clinical characterization of phenotypes remains challenging.
Therapeutic trials and cohort studies typically include patients with earlier disease
stages and exclude comorbidities, thus ignoring a substantial part of the real-world PD
population. To account for these limitations, we implemented the Luxembourg PD study
as a comprehensive clinical, molecular and device-based approach including patients
with typical PD and atypical parkinsonism, irrespective of their disease stage, age,
comorbidities, or linguistic background. To provide a large, longitudinally followed, and
deeply phenotyped set of patients and controls for clinical and fundamental research
on PD, we implemented an open-source digital platform that can be harmonized
with international PD cohort studies. Our interests also reflect Luxembourg-specific
areas of PD research, including vision, gait, and cognition. This effort is flanked by
comprehensive biosampling efforts assuring high quality and sustained availability of
body liquids and tissue biopsies. We provide evidence for the feasibility of such a
cohort program with deep phenotyping and high quality biosampling on parkinsonism
in an environment with structural specificities and alert the international research
community to our willingness to collaborate with other centers. The combination of
advanced clinical phenotyping approaches including device-based assessment will
create a comprehensive assessment of the disease and its variants, its interaction with
comorbidities and its progression. We envision the Luxembourg Parkinson’s study as an
important research platform for defining early diagnosis and progression markers that
translate into stratified treatment approaches.
Keywords: parkinsonism, cohort, longitudinal, stratification, deep phenotyping
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INTRODUCTION
Even 200 years after the first description of the diagnosis
of Parkinson’s disease (PD) (Dorsey et al., 2007), there are
substantial gaps in our understanding of the underlying
mechanisms and the complex clinical presentation of PD. The
differential diagnosis can remain challenging, especially at the
early stages of the disease; we still lack prognostic markers
predicting the disease trajectory and the treatment remains
symptomatic.
Consequently, strategies for defining novel treatment concepts
and improving the diagnostic accuracy at the early stages need to
account for the clinical and etiological heterogeneity of PD.
This clinical complexity defines the variable phenotypes of
the disease, which are represented by a variable combination
of different motor and non-motor symptoms and ranges from
early onset forms with slow disease progression and only few
axial symptoms to late-onset forms with early dementia and
gait disturbance (Krüger et al., 2016). Non-motor symptoms
receive more and more attention in the differentiation of subtypes
of the disease as these can precede the diagnosis for years.
Some of them have been therefore integrated in the research
criteria for prodromal PD (Berg et al., 2015), and can be used
to better stratify PD patients with implications on prognosis
and treatment response (Sauerbier et al., 2016). Amongst these,
cognitive impairment has gained more and more interest as
the cumulative incidence of dementia in PD reaches up to 80%
(Hely et al., 2008, cited by Yarnall et al., 2014). Here, it was
shown that 42.5% of newly diagnosed PD patients present already
with mild cognitive impairment (MCI), correlated with a with
a decrease of Abeta42 and Abeta40 levels in CSF (ICICLE-PD
study; Yarnall et al., 2014). As MCI increases the risk for
dementia, more data on biomarkers for cognitive impairment is
needed in order to enable accurate predictions for dementia. Rare
atypical parkinsonian syndromes, like Progressive Supranuclear
Palsy (PSP), Corticobasal Syndrome (CBS), or Multiple System
Atrophy (MSA) (Levin et al., 2016) represent common challenges
for differential diagnosis of PD, especially during early disease
stages (Ali and Morris, 2015; Lehosit and Cloud, 2015). Follow-up
is needed to definitely establish the diagnosis, and some patients
may only convert after more than 10 years from PD to atypical
parkinsonism (Petrovic et al., 2012). Currently, however, most
cohort studies are excluding patients with undefined atypical
parkinsonism (Mollenhauer et al., 2013; Szewczyk-Krolikowski
et al., 2014), although cohorts including them may better describe
the various possible disease trajectories.
Well in line with the etiological heterogeneity of the disease, an
increasing number of genes and environmental risk factors have
been identified, all playing a role in neurodegeneration in PD
(van der Brug et al., 2015; Elbaz et al., 2016). However, these are
still far from explaining the majority of PD cases, thus indicating
the need of well characterized cohorts to better define the natural
history of PD, to identify and validate biomarkers and to cluster
subgroups of patients for clinical trials. This need in mind, a
substantial number of observational studies in prodromal and
clinical PD have been initiated during the last years (Lerche et al.,
2015). Again, completeness of the clinical spectrum has not been
achieved by the respective recruitment strategies, as most of these
studies only included patients at the early disease stages (Lerche
et al., 2015; Malek et al., 2015), while more advanced PD stages
were underrepresented (Santos-García et al., 2016).
The risk for a recruitment bias is given, with inclusion of
phenocopies (e.g., subjects without evidence for dopaminergic
deficit, SWEDD) (Marshall et al., 2009), and persistent lack of
information on the natural disease progression in more advanced
stages of PD. Thus, inclusion of all disease stages and longitudinal
follow-up studies are crucial to address these knowledge gaps.
Moreover, the correlation of available genetic data with the
spectrum of clinical symptoms of PD is still limited (Grünewald,
2013). Existing studies focus either on genotyping with limited
availability of clinical data [e.g., age, gender and year of disease
onset in GWAS studies (Simón-Sánchez and Gasser, 2015)], or
on clinical phenotyping, with comprehensive clinical data, but
limited genetic information [i.e., DeNoPa (Mollenhauer et al.,
2013)]. In order to bridge this gap, studies combining deep
clinical phenotyping and a comprehensive assessment of genetic
and biological data are needed. Finally, in order to achieve
significant sample sizes that allow for validation across cohorts, a
harmonization in terms of scales, and/or, study design is required.
Already at the planning stage of a study, data harmonization with
other recruiting centers should be envisioned to validate findings
from different studies in a larger “collective” of patients.
Given the fact that the diagnostic and progression evaluation
of PD is still left to be fundamentally based on the clinical
assessment as defined by International Parkinson and Movement
Disorders Society (Postuma et al., 2015a), the urgent need for
biomarkers supporting the diagnosis, progression evaluation,
response to the therapy and finally specific subtype distribution
has become apparent. Biomarkers could be generally summarized
into 6 groups: diagnostic including the prodromal diagnostic
biomarkers as well early stage disease biomarkers, progression
biomarkers along with staging biomarkers, theragnostic
biomarkers reflecting the response to treatment and finally
stratification biomarkers as a base for translational research and
precision medicine with the ultimate goal to implement the
disease-modifying treatments.
Still ongoing research in biomarkers provides discrepancies
between the stratification of PD-subtypes based on clinical
phenotypes rather than biomarker-driven stratification. For
example, in the search for a diagnostic biomarker in CSF
using the data based on PPMI and DeNoPa cohort (Kang
et al., 2016; Mollenhauer et al., 2016), the CSF biomarkers of
clinically defined phenotypes have provided conflicting results
with substantial overlap with control group (Espay et al., 2017).
Moreover, the stability of the clinically defined phenotypes seems
to vary over time (Simuni et al., 2016) and therefore suggest a low
accuracy in defining reliable biomarkers. As for the prognostic
biomarkers, the presence of sleep disorders such as REM sleep
Behavior Disorder (RBD) has been widely investigated and
has been found to be associated with severe hyposmia, higher
frequency of non-motor symptoms, particularly depressive
syndromes and generally poorer prognosis (Zhou et al., 2016).
To address the above mentioned limitations, we designed the
Luxembourg Parkinson’s study, focusing on the recruitment of
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patients with PD and atypical parkinsonism at all disease stages
and directly planning for a long longitudinal a follow-up under
real world conditions.
Our study represents an ideal exploratory, a priori unbiased
by design cohort using a comprehensive longitudinal clinical
assessment accompanied by omics-based molecular fingerprints
analysis and combined with genotyping that will eventually allow
for a biomarker-driven stratification of PD in a well-defined
population.
Such a multidimensional approach ranging from genes and
complex molecular fingerprints to the longitudinal clinical
assessment promises to facilitate the detection of PD subtypes
and the disease-specific biomarkers on the way to the precision
medicine model. As a consequence, the well-defined subtypes of
PD are key to success in future clinical trials implementing the
disease modifying drugs.
This description of the program outlines the major axes of
data, strategies, and research approaches, in the context of a
national health initiative but also as an international source for
sharing and collaborative efforts in neurodegeneration research.
MATERIALS AND METHODS
Design
Type of the Study
The Luxembourg Parkinson’s study is a nation-wide,
monocentric, descriptive, observational, longitudinal-
prospective study with an annual follow-up of patients.
Control subjects will be followed up after 4 years. The baseline
evaluation is designed as case-control study, with an initial
recruitment period over 4 years.
Specific Goals
We focus on the comprehensive population-based recruitment
of all patients with parkinsonism in Luxembourg and the
surrounding ‘Greater Region’ (including the German, French,
and Belgian border regions). Recruitment and communication
strategies are tailored to the multilingual background of
participants, and include Luxembourgish, German, French,
English, and Portuguese as most popular languages.
Our specific tools allow us to focus on five main objectives
(Table 1).
Harmonization Strategy
Emphasis was put on harmonization of the datasets with
ongoing international cohort studies for comparability and cross
validation, thereby increasing statistical power of the planned
analyses. Therefore, the diagnostic criteria and scales applied in
our study, have been aligned with already existing international
cohort programs, e.g., DeNoPa (Mollenhauer et al., 2013),
Oxford PD Centre (OPDC) (Lawton et al., 2015); PPMI (Marek
et al., 2011), GEoPD (Puschmann et al., 2015), as described
previously (Lerche et al., 2015). Harmonization rates are shown
in Table 2.
To further increase the inter-comparability across the
above mentioned studies, we implemented different tests
with validated conversion procedures, i.e., MoCA/MMSE
TABLE 1 | Objectives.
Objective Tools Endpoints
Clinico-genetic stratification of
parkinsonism
- Deep clinical phenotyping (motor and non-motor) with
annual follow-up
- Genotyping (NeuroChip; Blauwendraat et al., 2017)
- Investigation of exposure factors
- Different disease stages
Disease history under real-world conditions
Stratification markers
Progression markers
Novel disease markers
Differential diagnosis of atypical
parkinsonism
- Inclusion of all atypical PD forms
- Inclusion of patients with conversion of diagnosis in
follow-up of
Conversion markers
Differential markers (IPD/atypical PD)
Early markers for the development of atypical parkinsonism
Identification of differential cognitive
profiles in PD and atypical PD
- Extensive cognitive phenotyping (five cognitive domains)
- Investigation of MCI/PDD MDS Level 2 criteria
- Tests to investigate cognition in atypical PD forms
- Assessment in different languages in a multilingual
population
- Establishment of population specific normative data
Cognitive markers for PDD and DLB
MCI-subtypes MCI-subtypes (executive, visuo-spatial,
amnestic dominant vs. multiple domain (Kalbe et al., 2016)
Early diagnostic markers for atypical PD forms
Risk/protective factors for dementia
Dissection of association between gait
disturbances and cognition
- Detailed assessment of gait including sensor based
measures [mPower (Trister et al., 2016), instrumental gait
analysis (Klucken et al., 2013; Schlachetzki et al., 2017)]
- In-depth and a continuous information collection about
disease progression
- Various aspects of gait can be linked to various cognition
factors
Validation of sensor based assessment for future clinical
trials Cognitive predictors for gait impairment
Definition of vision as an early disease
marker
- Detailed assessment of vision including color
discrimination, contrast sensitivity, and facial emotion
recognition (Diederich et al., 1998, 2010; Pieri et al.,
2000; Hipp et al., 2014)
Vision as an early marker of PD Facial emotion recognition
as a marker for PD
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TABLE 2 | Studies and percentage of common assessments with HELP-PD.
Study name % of tests integrated
in HELP-PD
LONG-PD (GEoPD, https://www.geopd.net) 93%
OPDC (http://opdc.medsci.ox.ac.uk) 73%
PPMI (https://www.michaeljfox.org) 67%
DeNoPa (visit 1) (http://www.denopa.de/) 56%
(van Steenoven et al., 2014), “Sniffin’ Sticks”/University
of Pennsylvania Smell Identification Test (UPSIT)
(Malek et al., 2017), UPDRS/MDS-UPDRS (Goetz et al.,
2012).
Communication Strategies
The implemented communication strategy aims to raise
awareness and spread information about the cohort study
to medical professionals, patients and the general public in
Luxembourg and the Greater Region. All communication
materials have been made available in five languages
(Luxembourgish, German, French, English, and Portuguese)
with German and French being by far the most favored
languages. To reach the communication objectives,
different communication channels have been established
(Table 3).
Recruitment Strategy
All the subjects have signed a written informed consent, and
the collection has been approved by the National Ethics Board
(CNER Ref: 201407/13) and Data Protection Committee (CNPD
Ref: 446/2017).
A clinical steering committee composed of different health
professionals from Luxembourg involved in PD care supervise
the recruitment procedures.
TABLE 3 | Communication channels developed.
Web Information
Dual-entry website (www.parkinson.lu) Research and medical professionals
Patients and control subject
Facebook site (Parkinson: Recherche
au Luxembourg)
Study update
Use of established social media
channels from partner institutions
Comprehensive NCER-PD video In German and French
explains the aims of the program and
gives an overview of the participation
steps and subsequent research
projects
Paper
Multilingual flyer and posters Information about PD, information
about study participation
Fact sheets Information on disease-related subjects
Bi-annual print newsletter Regular update of study and
Parkinson’s disease care and research
in general
Sample Size Calculation
Based on our sample size estimations, we will include 800 patients
with idiopathic PD or atypical parkinsonism, as well as 800
healthy control subjects.
The estimated prevalence and annual incidence of PD in
Luxembourg are 565–1,356 and 57–100, respectively, based on
available epidemiological data from other European countries
(von Campenhausen et al., 2005). Atypical forms of PD are
expected to be rare. For instance, for PSP we can only expect 7–25
patients in Luxembourg based on available data on prevalence
(von Campenhausen et al., 2005).
Assuming a type I error rate of 5% two sided and a power of
80%, 800 patients in each group would allow finding a significant
difference between groups. For instance, a two group χ2 test with
a 0.050 two-sided significance level will have 80% power to detect
the difference between a smaller proportion, pi1, of 0.010 and a
larger proportion,pi2, of 0.031 when the sample size in each group
is 800.
For instance if the proportion of MoCA < 26 is as low as
0.031 in the PD group and 0.010 in the non-PD (control) group,
800 patients in each group would allow to show a statistically
significant difference in cognitive impairment in the PD group.
Proportions of this estimated factor ranging from 1 to 20% in
the control group and the corresponding proportions in the PD
group for which a true difference would be detectable with the
target power are presented in Table 4.
However, for the within-cohort comparisons equality in
numbers of any subgroups being compared cannot be assumed.
Therefore, a minimum of 100 has been set for the smaller
subgroup of two being compared (with 700 for the larger).
Simulations of a series of differences between groups for a
particular character of interest gives a power of 82% that the
corresponding differences that can be detected. The Table 5
illustrates the situation where the larger probability is in the larger
group and the situation where the larger probability is in the
smaller group with the corresponding differences that can be
detected.
Therefore if we assume that the PD group is divided in
two categories (Hoehn and Yahr I and II or III and IV)
with probability of progression of 0.05 observed in the smaller
category (n = 100) and probability of progression is 0.134 in
the larger category, the difference of 0.084 could be shown
with a power of 81.9%. Genetic data would also be used here,
whereby the group of carriers of a specific variant with an
observed frequency of progression compared to the non-carriers
group.
Inclusion and Exclusion Criteria
Patient group
To be classified as idiopathic PD, patients must meet the inclusion
criteria proposed by the United Kingdom Parkinson’s Disease
TABLE 4 | Sample size for baseline comparisons.
Smaller proportion, pia 0.01 0.05 0.1 0.15 0.2
Larger proportion, pib 0.031 0.087 0.147 0.205 0.26
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TABLE 5 | Sample size for longitudinal within PD cohort comparisons.
Larger Prob. In larger group Larger Prob. In smaller group
Prob. group 1 Prob. group 2 (N = 700) Difference Attained power Prob. group 2 (N = 100) Difference Attained power
0,05 0,134 0,084 81,9 0,145 0,095 81,8
0,1 0,206 0,106 81,9 0,206 0,106 81,9
0,15 0,271 0,121 81,9 0,271 0,121 81,9
0,2 0,332 0,132 81,8 0,332 0,132 81,8
0,25 0,391 0,141 81,8 0,391 0,141 81,8
Society Brain Bank Clinical Diagnostic Criteria (Hughes et al.,
1992).
Patients who do not fulfill the proposed criteria will be
classified as unspecified PD or as atypical PD based on
the respective criteria. In the atypical PD subgroup, further
classification will include subtypes, including PSP (Litvan et al.,
1996; Höglinger et al., 2017), MSA (Gilman et al., 2008), CBS
(Boeve et al., 2003) or vascular parkinsonism (VP) (Zijlmans
et al., 2004), based on internationally established criteria. All
diagnostic classifications will be regularly updated. Patients with
essential tremor are excluded from the patients group, and
included into the control group. They may convert into typical
PD and would then qualify for the inclusion into the patient
group (Unal Gulsuner et al., 2014; Laroia and Louis, 2011).
Patients with a secondary cause of parkinsonism (e.g.,
normal pressure hydrocephalus, toxic parkinsonism,
medication-induced parkinsonism, symptomatic parkinsonism
due to structural lesions) are excluded. Here, separation was
based on established diagnostic criteria that include clinical
symptoms as well as available clinical imaging results. Whereas
normal pressure hydrocephalus may still be clinically over
suspected (Espay et al., 2017), and presents with parkinsonism,
gait disturbance, urinary symptoms, as observed for VP, the
cardiovascular risk profile and the typical imaging findings with
vascular lesions vs. symmetric enlargement of ventricles and
diapedesis of CSF defines the difference of both secondary causes
of parkinsonism (Rektor et al., 2018).
Healthy control group
Healthy control subjects are recruited and matched for age and
gender via continuous statistical calculations. Subjects with a
neurodegenerative disease are excluded (c.f. Table 6). Controls
include spouses of patients and unrelated volunteers who are
partially recruited from a pool of healthy controls previously
participating in independent Luxembourgish observational
studies such as the ORISCAV-LUX study (Crichton and
Alkerwi, 2014) or EHES-LUX, the 2013 Luxembourgish
part of the European Health Examination Survey (EHES)
study (Kuulasmaa et al., 2012; Ruiz-Castell et al., 2016).
The Frequency of PD patients stratified by age, gender,
residence and BMI is calculated at regular intervals and
the recruitment of healthy control subjects is subsequently
oriented toward having a match between newly recruited
PD patients and healthy controls and can be adjusted via
available subjects in the previous described epidemiological
studies.
The Flexible Participation Concept
To account for potential variable motivation of the heterogeneous
population in Luxembourg and to improve adherence to our
study, we implemented a flexible participation concept. Here,
the participants can choose between different participation levels
concerning clinical assessments and biosampling, by offering
a basic assessment level (Level A) that is mandatory for all
participants, and an optional assessment level (Level B) including
a variety of focused assessments detailed below and focusing
more specifically on vision, gait or specific aspects of PSP. Level
B also proposes more invasive biosampling such as lumbar
puncture or skin biopsy (Figure 1). Level A assessment and
biosampling are carried out during one visit of 2–3 h. The
Level B tests and the optional biosampling are performed during
independent visits not exceeding 2 h in total (Figure 1).
Mobile Recruitment Team
Participants are recruited either at the research center site or at
different sites in Luxembourg and the Greater Region defined as
“hubs” that are attended by a mobile recruitment team (“flying
team”) allowing participants to be recruited closer to their home
area avoiding transport issues.
In case a patient cannot join for a follow-up visit, neither
at the center, nor by the mobile recruitment team, e.g.,
because of extremely reduced mobility, or living too far away
from the recruitment area, a standardized telephone or Skype
questionnaire is proposed containing a reduced assessment of
Level A.
Assessments
Clinical Phenotyping
Motor function and motor complications are assessed by using
self-reported questionnaires, rating scales and standardized
objective test measures. Sensor based assessments have been
integrated to address multiple variables of bradykinesia and gait
(Table 7). We assess non-motor, e.g., dysautonomic symptoms and
their impact on activities of daily living and quality of life by using
self-reported questionnaires (Table 8). Global cognitive function
is assessed with the MoCA test. Additionally each of the five
cognitive domains (executive, memory, attention, visuo-spatial,
and language), is assessed by two tests according to the Level 2
criteria for sub-typing classification for MCI (Litvan et al., 2012)
and PD with dementia (PDD) (Dubois et al., 2007). The executive
functions with the sub-domains planning, initiation, inhibition,
set shifting, and conceptualization are explored in detail. In the
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FIGURE 1 | Flexible participation concept.
TABLE 6 | Inclusion and exclusion criteria.
Patients Controls
Inclusion criteria Diagnosis of parkinsonism Subjects without ND disease
>18 years of age >18 years of age
Exclusion criteria Absence of parkinsonism Presence of neurodegenerative
disorder
Symptomatic parkinsonism
Active cancer Active cancer
Pregnant women Pregnant women
Limited capacity of consent on the part of the subject, if
there is no legally determined tutor
visuo-spatial domain our test battery will allow to differentiate
between perceptive and constructive abilities (Table 9). Finally
the assessment of sensory function encompasses tests for odor and
vision (Table 10).
If available from the clinical records, the information on
previous clinical imaging (CT, MRI, DaTSCANTM) was recorded
in the electronic case report form (eCRF).
Sensor Based Measures
Device-based assessments (DBA) allow the objective longitudinal
registration of relevant short term and gradual changes related to
disease stage and progression of a patient’s clinical state. These
changes may sometimes remain undetected in a conventional,
“snap-shot” clinical setting.
These technologies provide an objective, time- and
cost-effective approach and initial data from stand-alone
mPower in the United States is promising (Figures 1, 3 d+e),
however, the validation and correlation of sensor-based data with
standardized clinical assessments in large, well-described cohorts
remain a major need to translate into clinical decision support.
We focused on two strategies, (i) a mobile phone application
capturing data from the home environment of participants
and (ii) a gait sensor used for lab-monitoring under controlled
conditions at the recruitment hub.
For the first, we integrated the mPower application into the
database of our Luxembourg Parkinson’s Study to add to the
deep phenotyping of our cohort. This application combines
a traditional survey-based approach with data gained through
continuous sensor-based measurements, as well as task-based
assessments (Bot et al., 2016). Anonymized longitudinal data
from the application will be then correlated with longitudinal
clinical and biological data in our database. It is an objective,
time- and cost-effective approach, which will allow (i) to offer
a more direct participation in our research, (ii) to define
participant’s adherence to new technologies and (iii) to validate
sensor-based algorithms with clinical data from standardized
assessments in large cohorts of patients.
Wearable sensors were integrated by using a shoe equipped
with a sensor to assess different aspects of gait during
standardized gait tasks [instrumental gait analysis (Klucken
et al., 2013; Schlachetzki et al., 2017)]. This lab-monitoring
approach is implemented in the clinical visit and therefore
the sensor-based assessment is paired with a structured clinical
assessment of gait (Table 7), in order to allow for validation.
Therefore a technological environment for capturing data and
transferring to the study database was developed. In a second
step these sensor-based gait monitorings should be transferred
into the home environment of patients, to provide more ‘real life’
kinematic data allowing for classification of patients.
The implemented technologies will be a first step toward
rater-independent appraisal of parkinsonian symptoms and
support stratification of patients into subgroups.
Questionnaires on Environmental Factors
Environmental exposure data are collected through a modified
version of the self-administered questionnaire with reference to
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TABLE 7 | Assessment tools for motor function.
Self-reported Rating scale Objective measure
Global motor +MDS-UPDRS III and + IV
Bradykinesia +MDS-UPDRS III mPower tapping activity (Trister et al.,
2016)
Fine/gross motor and coordination +Purdue Pegboard∗ (Tiffin and Asher,
1948)
Gait-general +MDS-UPDRS III Timed up and go
mPower walking activity
Freezing of gait Freezing of Gait Questionnaire
New freezing of Gait Questionnaire
+MDS-UPDRS III
Freezing of gait assessment course
(Ziegler et al., 2010)
Instrumental gait assessment (Klucken
et al., 2013)
PSP specific motor dysfunction Unified PSP Rating Scale (Golbe and
Ohman-Strickland, 2007)
+ Included in Level A (mandatory) assessment.
TABLE 8 | Questionnaires for non-motor symptoms in PD.
Function/symptom Test
Global General non-motor symptoms +Parkinson’s Disease Non-Motor Questionnaire (PD-NMS)
Psychiatric symptoms Depression +Beck Depression Inventory (BDI)
Apathy +Starkstein Apathy Scale (SAS)
Dysautonomic function Including, e.g., constipation, daytime somnolence,
symptomatic hypotension, erectile and urinary dysfunction
+SCOPA-AUT
Sleep General +Parkinson’s Disease Sleeping Scale (PDSS)
REM sleep Behavior Disorder (RBD) +RBD Screening Questionnaire (RBDSQ)
Quality of life Eight disease-related issues: mobility, activities of daily
living, emotional well-being, stigma, social support
cognitions, communication, and bodily discomfort
+Parkinson’s Disease Quality of Life Questionnaire (PD-QoL-39)
+ Included in Level A (mandatory) assessment.
the PD Risk Factor Questionnaire (PD-RFQ-U) Epi InfoTM |
CDC1 of which the main questions have been extracted. We thus
assess the exposures potentially relevant in our cohort such as
caffeine, tobacco, alcohol, pesticide, anti-inflammatory agents,
and hormonal medications. Residential and occupational history,
physical activity and body habitus are evaluated by the same
questionnaire. The Family history addresses PD, essential tremor,
Alzheimer’s disease (AD) and more generally, dementias.
Broad genetic analyses for PD-associated mutations will be
performed using NeuroChip technology (Blauwendraat et al.,
2017), a genotyping array that allows to analyze 306,670 variants
and it provides a manually curated custom content comprising
179,467 variants. This approach allows to screen for all currently
known genetic risk variants for different neurodegenerative
diseases, including PD, Dementia with Levy Bodies (DLB), AD,
and Amyotrophic Lateral Sclerosis (ALS).
Assessment of Omics
Biospecimens are collected from patients and healthy controls
at each visit using standardized collection kits, with blood,
urine, saliva as part of the mandatory sampling (Figure 1). In
addition, optional specimens including stool, skin biopsies and
CSF can be collected. From the different biomaterials, we are
1https://www.cdc.gov/epiinfo/index.html
able to derive iPSCs and different omics (Figure 2). Biospecimens
are processed following Standard Operating Procedures (SOPs)
(for details, see Supplementary Tables A, B) (Lehmann et al.,
2012). All samples are stored at the Integrated BioBank
Luxembourg (IBBL) and the details of storage conditions
as well as all sample related annotations are captured in
electronic databases. As sample quality is critical for the
reproducibility and reliability of experimental results, IBBL has
implemented validation and quality checks at all critical steps.
They are continuously updated and extended, as needed (see
Supplementary Tables).
Data Analysis and Management
Endpoints
The data-driven and not hypothesis-driven analysis should allow
us to detect yet unknown biomarkers identifying clusters or
subgroups of patients with specific clinical trajectories, possibly
coupled to defined omics’ characteristics. The longitudinal design
of our study should allow further validation of the identified
biomarkers. Specifically, the presence of certain markers at
baseline will be correlated with the progression of the disease and
to its different clinical patterns.
Besides standard statistical approaches (distributions,
correlations, or independence tests), we are planning to employ
well-grounded machine learning methods integrated into our
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TABLE 9 | Tests used to assess cognition.
Domain Function Test
Global cognition +Montréal Cognitive
Assessment (MoCA)
Attention/working
memory
Visual attention +TMT∗-A
Divided (visual/auditory
attention)
TAP∗∗-Divided Attention
Visuospatial short-term
memory
Block spans (forward)
Auditory short-term
memory
Digit spans (forward)
Visuo-spatial working
memory
Block spans (backward)
Auditory working memory Digit spans (backward)
Executive Mental flexibility/set shifting +TMT-B
TAP-Flexibility
Set Test (Isaak)
Automatic response
inhibition
STROOP test (Kaplan)
TAP-Go/No-go
Planning +Clock Test – Placement of
numbers
Conceptualization Similarities (+MoCA, FAB)
Frontal functions Frontal Assessment Battery
(FAB)
Response initiation +Letter Fluency F (MoCA)
Letter Fluency S (FAB)
Memory Verbal learning + episodic
memory consolidation
Immediate and delayed
word list recall (CERAD)
Word Recognition (CERAD)
Visuospatial Visuo-perception Benton’s Judgment of Line
Orientation
Visuo-construction +Wire Cube (MoCA)
Interlocking Pentagons
(MMSE)
+Clock Test (MoCA)
Language Language access Category Fluency (animals)
GREMOTs denomination of
36 substantives and 36
verbs
+ Included in Level A (mandatory) assessment. ∗Trail Making Test, ∗∗Test of
Attention Performance.
TABLE 10 | Tests used to assess sensory function.
Function Test
Odor identification +Burghart Sniffin’ Sticks – 16 items identification test
Color discrimination Farnsworth Munsell 100 Hue test
Contrast sensitivity Pelli Robson Letter Chart
Kybervision Contrast Sensitivity (Beaudot, 2009)
Facial emotion recognition Ekman 60 Faces Test
+ Included in Level A (mandatory) assessment.
data exploration and analytic platform, Ada2 using Spark ML
library. This covers a wide variety of classification, regression,
clusterization, feature selection, normalization, and time-series
2https://ada.parkinson.lu
processing routines. We opted for Spark since it is a popular
computational grid library for an efficient large-scale data
processing and analysis. Ada’s computational infrastructure
together with a convenient UI opens the advanced analytics and
machine learning to a diverse group of researchers, clinicians,
and statisticians.
Data Management
To provide sustained resource for research on PD, we
implemented an advanced IT infrastructure that accounts for
the heterogeneity of data (e.g., clinical, epidemiological, and
biological) and the amount of data requiring an adapted strategy
for big data management and visualization.
All clinical data and biosample metadata are collected and
managed using electronic data capture tools developed and
maintained by the LCSB (Harris et al., 2009) (Figure 3).
REDCap is a web-based application designed to support
data capture for research studies. We have developed an eCRF
in the REDCap framework that allows for centralized storage,
high security and cost savings when compared to traditional
paper-based approaches. In order to make it secure, our PD
REDCap instance is encrypted, site restricted and controlled
access with two-factor authentication.
A reporting system (Ada), developed in-house, provides key
infrastructure for secured integration, visualization, and analysis
of heterogeneous clinical and experimental data through the
study. The platform currently manages anonymized data sets
associated with clinical research pulled from REDCap system,
biosampling-related information provided by IBBL, and kinetic
data from mPower mobile application and gait sensors. As Ada
also hosts DeNoPa study clinical data (three visits, Mollenhauer
et al., 2013), it is a unique tool for future cross-study analyses
and validations. DeNoPa dataset was therefore translated from
German to English, curated for content and harmonized with the
our eCRF.
Ada’s main features include a convenient web interface for
dataset exploration and filtering, and configurable views with
tables and charts showing basic statistics, such as, distributions,
scatters, correlations, and box plots. To define dataset’s metadata
Ada provides an editable dictionary, and a category tree
with drag-and-drop manipulation [i2b2 – Informatics for
Integrating Biology and the Bedside (Murphy et al., 2009, 2010)].
Furthermore, Ada facilitates robust access control through
state-of-the-art authentication layer, and user management with
fine-grained permissions.
The curated datasets are also integrated into a dedicated
tranSMART system that supports cohort based integrated
analysis and hypothesis generation.
Quality Management
Clinical assessments via raters experienced in the diagnosis of
movement disorders still imply the risk of interrater variability.
Here apparently the early stages of PD with only mild
clinical symptoms impose the highest challenge for uniform
rating results (Goetz et al., 2004). In order to assure high
data quality and minimize interrater variability we integrated
a constant benchmarking against the MDS-UPDRS training
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FIGURE 2 | Omics assessment. ∗PBMC: Peripheral Blood Mononuclear Cell, ∗∗ iPSC: induced pluripotent stem cells.
FIGURE 3 | Data and sample flow in ND-collection. Subject personal data is securely collected and only the clinical team has access to that data. The clinical team
generates a primary pseudonym and binds it to the subject’s personal record. The clinical data is deposited into REDCap, the Electronic Data Capturing (EDC)
system, along with the pseudonym and the barcodes of the samples which are also recorded in the REDCap system. Sample Annotations go into the Data
Integration and Analysis Platform which is a part of the Data and Computing Platform hosted at the LCSB in a secure data center. Within the Data and Computing
Platform at the LCSB, the pseudonymized clinical data from REDCap is accessed by the Data Integration and Analysis Platform via an Application Programming
Interface. As part of the direct clinical assessment, the kinetic gait data from the shoe sensors is deposited using the primary pseudonym generated by clinical team
at the PRC.
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videos and regularly perform joint ratings by two independent
staff members. Furthermore, we regularly perform internal
video-assisted training sessions for the use of the assessment tools
addressing difficult cases to ensure adherence to standardized
procedures by all raters from the team.
Additionally, the REDCap system includes constraints in data
fields and alerts in case of uncompleted data fields. Moreover,
an independent study monitor performs regular source data
verifications as well as verifications of completeness of predefined
essential data.
Our REDCap database system is set up for sharing and
harmonizing clinical and experimental data across different
international sites. Moreover, a subset is available as minimal
dataset within the Genetic Epidemiology of Parkinson’s disease
(GEoPD Consortium3) providing data ownership for individual
sites, but also options for joint analyses along harmonized
datasets.
RESULTS
So far, we have included 498 patients and 520 healthy control
subjects according to the recruitment plan. Ninety-four (14.1%)
patients have been assessed by the flying team at one of
our recruitment hubs. Currently, the recruitment numbers
correspond to 101.8% of the initial recruitment plan and indicates
the efficiency of our strategy.
At yearly follow-up, 229 patients have accomplished a second,
and 92 a third visit. Over all the visits, 38 patients (8.9%) have
been lost to follow-up for a given visit. 94 (14.1%) patients have
been assessed by the flying team at one of our recruitment hubs.
The reduced telephone questionnaire has been performed in 11
patients for the first, and in 10 for the second follow-up. Within
the interval of 29 months a total of 13 patients deceased, nine
after their first and four after their second visit. The reasons
for death were pneumonia (one case), cardio-respiratory failure
(three cases), septicemia (one case), or not available (seven
cases).
The participation in Level B assessments and optional sample
collection are relatively high even if proposed optionally (e.g., 896
stool samples) (Table 11).
3www.geopd.net
TABLE 11 | Participation numbers in Level B.
PD patients N Healthy
controls N
Total N
Visit 1 Visit 2 Visit 3
Level B
neuropsychology
192 29 4 252 477
Level B gait 137 99 63 87 386
Level B vision 75 37 7 95 214
Level B PSP
assessment
8 0 0 0 8
Stool 280 162 60 394 896
Skin biopsy 58 26 11 69 164
At this stage, the patient group is composed of 422 (84.6%)
IPD (44 with PDD), 7 (1.4%) DLB, 4 (0.8%) MSA, 6 (1.2%) CBS
and 26 (5.2%) PSP patients. Our inclusion criteria allowed thus to
include already 15% patients with confirmed or probable atypical
forms of parkinsonism, and at follow-up, the first converters form
IPD to PSP could already be identified.
We achieved a representation of patients form all disease
stages, including the advanced ones. More than a third of the
patients have H&Y > 2 (37.2%) and still 12.6% show H&Y > 3.
Median H&Y stage is 2 with a range from 1 to 5 (46.7% with 2).
Mean disease duration is 6.45 ± 5.44 years with a range from
de novo patients to 30 years of disease duration.
Concerning the socio-cultural level, the accomplished
education-years in the patient group reach from 1 to 30 years
(mean: 12.57± 4.1).
Except for the Luxembourgish language, which is the most
represented first language in our population with 62%, German
and French being the second most represented (13% and 15%,
respectively). In most of the population (82%) they are either
the first or the second best spoken language. This means that
we cover 82% of our population with the use of assessment tools
in German and French. The remaining 18% proportion can be
covered by the use of English assessment tools (English as first or
second language, 16%). Only a minor proportion (2%) cannot be
reached by any of these three languages. Here, we adapt by orally
translating parts of the assessment in their language.
In terms of harmonization of data we successfully aligned
data dictionaries within the REDCap databases with the Oxford
Parkinson’s Disease Centre (OPDC; United Kingdom) and the
Tübingen Parkinson’s Programme (ABC-PD; Germany). These
are currently used for cross-validation of neuropsychological
features and questionnaires across different study sites.
DISCUSSION
The Luxembourg Parkinson’s Study aims to combine
comprehensive and longitudinally collected clinical data
with emerging experimental data and biomarker programs.
The aim is to bridge the gap between molecular information
and clinical phenotype in PD, by integrating multidisciplinary
competences in the area of clinical research, biomedical IT,
computational modeling, and fundamental research including
innovative technologies.
Our study in Luxembourg and the Greater Region exemplifies
the feasibility of a cohort program with both deep clinical
phenotyping and high quality biosampling on parkinsonism in
an environment with limited exposure to clinical research. The
success of the adapted recruitment strategy, including the concept
of flexible participation, is reflected by the achievement of the
initial recruitment goals, the high level of adherence of the
participants and even the high level of participation to Level
B. Here, the concept of a network structure represented by
a ‘center without walls,’ involving stakeholders from different
areas of healthcare (hospitals, private practices, nursing homes,
different health professionals, and representatives from various
research institutes, was largely accepted and contributed to the
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success, instead of a geographically limited ‘center with walls.’)
The pioneering character within the implementation process
also relates to the administrative framework and includes an
Institutional Review Board (IRB) procedure that contributed
to the development of a first IRB guideline for the handling
of genetic incidental findings occurring during next generation
sequencing in Luxembourg. Another added value was the
establishment of data protection procedures including the
possibility of exchange of pseudonymized data within scientific
collaborations. Our study adds to current cohort designs that
either perform deep genetic stratification in large cohorts of
PD patients with only limited clinical information (e.g., age,
age at onset, gender, and family history) (Nalls et al., 2014) or
perform deep clinical phenotyping in cohorts not genetically
assessed (Lerche et al., 2016). Here, the implementation of
the new NeuroChip technology allows the comprehensive
testing of all currently known disease genes and risk variants
related to the most common neurodegenerative disorders
(Blauwendraat et al., 2017). Therefore also potential overlap of
pathomechanisms between different neurological diseases may
be detected, as recently shown for PD, frontotemporal dementia
with parkinsonism (FTDP) and Alzheimer’s disease (AD) (Ferrari
et al., 2017). Indeed different forms of parkinsonism with
a shared molecular background have been identified, e.g.,
mutations in the LRRK2 gene were described as causing
typical PD, MSA or PSP with histopathological features ranging
from synucleinopathies up to tau aggregation (Zimprich et al.,
2004).
To define our cohort, we referred to the UK PD brain bank
criteria, as the new MDS criteria were not available at the time
defining the protocol of our study (Postuma et al., 2015a). As
the harmonization and validation of our dataset according to
different scales is a major aim of our study, we will perform
comparisons of the different diagnostic criteria to delineate
potential differences in sensitivity and specificity.
The strategy to include all stages of PD and atypical forms of
parkinsonism opens new avenues to investigate the longitudinal
course of the respective diseases, and to define predictors of
conversion between typical and atypical parkinsonism. However,
this also implies the risk of loss to follow-up due to increased
morbidity and mortality in advanced disease stages (Fielding
et al., 2016). To reduce this risk we included a flexible
participation principle either by a flying team allowing patients
to participate close to their home environment or, for the most
disabled, offering a phone interview with reduced datasets instead
of a visit.
We have also demonstrated the feasibility of recruiting PD
and atypical parkinsonism in one study. Due to the relatively low
prevalence of atypical parkinsonism, considered thus as orphan
diseases, there is a lack of population-based comprehensive
data for direct comparison to PD (Wenning et al., 2013).
As this frequently imposes problems for differential diagnosis,
especially in early disease stages, our strategy not only provides
different control groups (healthy and diseased) and avoids
the drop out of PD patients developing atypical symptoms
over time opposed to other ongoing studies (Petrovic et al.,
2012). This integrative approach enables us to compare the
different forms of parkinsonism, and thus to identify new
disease markers (e.g., in the cognitive domain) that could lead
to a more accurate differential diagnosis at earlier disease
stages.
The deep phenotyping approach implemented in our study
by management of big data enables us to adopt a data
driven approach, compared to, e.g., other studies investigating
prodromal PD that are focusing on theory driven aspects which
can imply limitations. Theory-driven research explores in much
detail RBD, considered to be a prominent forerunner syndrome
marker (Postuma et al., 2015b). Even if the risk of PD is highly
increased in individuals with an RBD (30% after 3 years to
66% after 7.5 years), its frequency in PD is not clear. A recent
meta-analysis found a pooled prevalence 42.3% of RBD in
PD (Zhang et al., 2017). Furthermore, RBD is also found in
other synucleinopathies like MSA (Zhang et al., 2017) or DLB
(Fereshtehnejad et al., 2017). This discrepancy is leading to a bias
in disease characterization, because risk cohorts are representing
a specific profile and not reflecting the whole spectrum of
parkinsonian syndromes. Here a more data-driven approach will
enable us to address new concepts for risk cohorts including
the whole spectrum of the disease and avoid biases due to
theory-driven approaches.
The multilingual background of participants in our study
allows for (i) further investigating the concept of cognitive reserve
in neurodegenerative diseases, a concept postulated previously
in Luxembourg (Perquin et al., 2013, 2015), and (ii) for the
validation of screening tools across languages and provides
opportunities for expanding the internationally available tools for
clinical research in the area of PD [e.g., validation of the French
Munich Dysphagia Test (Hipp et al., 2017)].
As a monocentric study, an advantage over the majority of
other nation-wide cohort studies is the low variability and high
quality of collected data because of the defined number of raters.
Our program has been designed specifically to allow
international collaborations and we successfully implemented
shared datasets within REDCap across study centers in Oxford
(OPDC) and Tübingen (ABC-PD). In this context, we set up
an infrastructure for accepting applications for data sharing,
sample sharing and group intellectual sharing that will foster
international collaborations.
Among the limitations of our current approach is the
lack of a comprehensive imaging and brain banking program
that allow for structural and functional image analyses and
histopathological confirmation of the diagnosis. This was already
partly recognized and the first brain banking program in
Luxembourg is currently set up and will allow study participants
to donate their brains for research.
The Luxembourg Parkinson’s study will provide a valuable
contribution to the international ongoing cohorts and allow
cross-validation of emerging results for stratification in PD.
Indeed first studies in large cohorts of PD patients allowed to
identify “new” subtypes of PD with differing courses of disease
progression (von Campenhausen et al., 2005). This was possible
due to integration of clinical and biological data and allowed
the identification of a more malignant form of PD with more
pronounced dopaminergic deficit, increased brain atrophy and
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an Alzheimer’s disease-like profile of cerebrospinal fluid that
was related to faster progression of motor and cognitive deficits.
These findings require validation in independent cohorts across
different populations worldwide.
Our preliminary results underscore the feasibility of the study
considering the efficiency of the actually adapted strategies and
estimation of the population composition in the investigated
region, and the realization of this cohort study will be efficient
and provide comprehensive data on PD in many aspects.
Moreover, the well-characterized patients with PD and atypical
parkinsonism in our study will open access to new therapies
via more focused clinical trials disease subgroups in the
future.
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